Clinical Trial Update: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study [Phase 2]

View source ↗

Summary

Phase II IMMUNOSABR trial testing immunotherapy with stereotactic ablative radiotherapy for stage IV non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Maastricht University Medical Center | Conditions: NSCLC Stage IV, Metastatic Disease | Phase 2 | Status: TERMINATED